Rumalon®

Active substance:

glycosaminoglycan-peptide complex produced from cartilage extract and calf bone marrow extract

Pharmachologic effect:

stimulating cartilage regeneration.

Pharmacodynamics:

Rumalon is a combined preparation of animal origin, contains a glycosaminoglycan-peptide complex. The action of the drug is due to the combined action of its active components. Rumalon normalizes metabolism in cartilage hyaline tissue: enhances the biosynthesis of sulfated mucopolysaccharides and collagen, stimulates the regeneration of articular cartilage, reduces enzyme activity and inhibits catabolic processes in cartilage tissue.

Indications:

Degenerative-dystrophic diseases of the joints: gonarthrosis, arthrosis of the interphalangeal joints, coxarthrosis, spondylosis, spondylarthrosis, meniscopathy, chondromalacia of the patella.

Contraindications:

hypersensitivity to the components of the drug;
rheumatoid arthritis;
use in women of reproductive age who do not comply with reliable methods of contraception;
pregnancy;
breastfeeding period;
age up to 18 years.

Pregnancy and breast-feeding:

The use of the drug during pregnancy and during breastfeeding is contraindicated (due to the lack of information on the use of the drug in these groups of patients).

Side effects:

rarely - allergic reactions, incl. anaphylactoid reactions, anaphylactic shock.

Interaction:

Rumalon® can be used simultaneously with non-steroidal anti-inflammatory drugs and glucocorticosteroids.
Simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, enchances their action.

Dosing and Administration:

Intramuscularly (deeply) on the first day - 0.3 ml, on the second day - 0.5 ml, and then 3 times a week, 1 ml for 5-6 weeks. Repeated course of treatment - after consulting a doctor according to the same scheme.

Write a review

Please login to review